Phase 3 N=935 Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
COVID-19
Primary: Time to Sustained Clinical Recovery — 13.3; 12.4 days — p=0.8786
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=57 Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients
Hereditary Angioedema
Primary: Time to Beginning of Relief Based on Visual Analogue Scale (VAS) Was Defined as the Time, in Minutes, From Time of Infusion to the Beginning of Relief. — 60 minutes
N/A N=50 Diet and Hereditary Haemorrhagic Telangiectasia
Hereditary Haemorrhagic Telangiectasia (HHT)
Primary: Number of Participants That Achieving Personal Recommended Intake of Iron — 43 Participants
Phase 3 N=1,187 The Prevent Severe COVID-19 (PRESECO) Study
Covid19
Primary: Number of Participants With Sustained Clinical Recovery — 425; 475 Participants
N/A N=520 AMPLATZER™ LAA Occluder Post Approval Study (PAS)
Atrial Fibrillation · Thromboembolism · Stroke
Primary: Primary Effectiveness Endpoint 1: Composite Rate of Stroke (Including Ischemic or Hemorrhagic), Systemic Embolism and Cardiovascular or Unexplained Death — 14.28…
Phase 4 N=110 Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19
Covid19
Primary: Number of Participants With Clinical Improvement of Greater Than or Equal to 2 Points Using the WHO-OSCI at Day 28 — 37; 43 Participants
N/A N=1,901 A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice
Colitis, Ulcerative · Crohn Disease · Inflammatory Bowel Diseases
Primary: Number of Participants Stratified by Treatment Patterns Associated With Biologics Agents Use or Non-biological Therapy in Participants With Moderate to Severe UC and CD…
Phase 1 N=27 Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
Breast Cancer · Pancreatic Cancer · Colorectal Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 3; 4; 5; 7 Participants
Phase 2 N=7 A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)
Nonalcoholic Steatohepatitis (NASH)
Primary: Number of Participants With Treatment-related Adverse Events. — 3 Participants
N/A N=201 HD Mapping of Atrial Fibrillation in Asia Pacific
Paroxysmal Atrial Fibrillation · Persistent Atrial Fibrillation
Primary: Number of Participants With Acute Success of RF Ablation After Electroanatomical Mapping With HD Mapping Catheters. — 173 Participants
N/A N=35 The Evaluation of Thrombogenicity in Patients Undergoing WATCHMAN Left Atrial Appendage Closure Trial
Left Atrial Appendage Closure · WATCHMAN Device Implantation
Primary: Comparison of Thrombin Induced Platelet-fibrin Clot Strength (TIP-FCS) Between Patients With and Without Device Related Thrombosis (DRT) Assessed at 1-year of Watchman…
Phase 1 N=23 A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus · Lupus Erythematosus, Systemic
Primary: Number of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE) — 3; 4; 6; 2 Participants
Phase 4 N=41 Safety and Efficacy of Chronic Hypnotic Use 2
Chronic Insomnia
Primary: Total Number of Capsules Taken During Discontinuation From Either Active Drug vs Placebo Over a Two Week Period — 0.43; 2.6; 6.3 Total number capsules chosen — p==0.05
N/A N=58 Cartesia eXTend 3D Study
Parkinson Disease
Primary: Change in Motor Function — -19.9 units on a scale
N/A N=38 Clinical Study to Evaluate the Efficacy of an Over-the-counter (OTC) Sunscreen Lip Balm Product
Sunscreening Agents
Primary: Mean Change From Baseline in Corneometer Measurements — 23.5; 24.2; 2.4; -0.6 Arbitrary units — p=<0.0001